Effect of oral vitamin C on serum hepcidin level, iron status and inflammation among hemodialysis patients with functional iron deficiency anaemia

Publish Year: 1400
نوع سند: مقاله ژورنالی
زبان: English
View: 150

This Paper With 7 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_JRE-7-1_016

تاریخ نمایه سازی: 30 مرداد 1401

Abstract:

Introduction: Hepcidin is a key regulatory peptide in iron homeostasis, the pathogenesis of functional iron deficiency (FID) anemia and erythropoiesis-stimulating agent (ESA) resistance is contributed to the inflammatory mediated increase in the serum hepcidin levels among prevalent hemodialysis (HD) patients.Objectives: To test the reducing therapeutic effect of oral vitamin C supplements on hepcidin levels and iron status among HD patients with FID anemia.Patients and Methods: This study is an interventional prospective cohort study; ۴۸ prevalent HD patients were enrolled. Group one: ۳۱ patients who received the conventional treatment of erythropoietin stimulating agents together with oral supplementation of vitamin C ۵۰۰ mg every other day dose for ۳ months. Group two: ۱۷ patients who received only the conventional therapy of erythropoietin stimulating agents. Patients with hemoglobin level <۱۱ g/dL, ferritin level >۲۰۰ ng/mL and transferrin saturation (TSAT) >۲۰ % were included. Laboratory parameters: serum hepcidin, high-sensitivity C-reactive protein (hs-CRP) titre, CBC, and iron indices were measured at baseline and after ۳ months.Results: On comparing the two groups, oral vitamin C in group ۱ resulted in a statistically significant reduction in hepcidin levels [mean ۲۵۰۶.۴۵۶ ± ۱۳۲۰.۵۳ pg/mL to ۱۷۴۸.۳۹۶ ± ۱۴۳۲.۲۸ pg/mL (P = ۰.۰۳)], and a significant reduction in hs-CRP level [mean ۸۶۰۳.۲۳۶ ± ۲۵۴۷.۷۷ ng/mL to ۵۶۱۱.۲۹۶ ± ۲۸۲۹.۲۷ ng/mL] (P = ۰.۰۰۱) after three months of treatment in comparison to control group. A decrease of EPO requirement and elevation of hemoglobin level were observed in a study group with oral vitamin C.Conclusion: Oral vitamin C may be a promising therapy in decreasing serum hepcidin and inflammatory markers among prevalent HD patients with FID anemia.

Authors

Maha A. Behairy

Internal Medicine and Nephrology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt

Ahmed Gharib

Internal Medicine and Nephrology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt

Mahmoud Zaki

Internal Medicine and Nephrology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt

Reem El Sharabasy

Internal Medicine and Nephrology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt